CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
CStone Pharmaceuticals
Asan Medical Center
Novartis
Medical University Innsbruck
National Cancer Institute (NCI)
University of Helsinki
European Organisation for Research and Treatment of Cancer - EORTC
Northwestern University
Northwestern University
FeRx